Potent and selective dual reuptake inhibitor at dopamine and norepinephrine transporters that increases extracellular levels of DA and NE in vivo
Solriamfetol (JZP-110) is a potent and selective dual reuptake inhibitor at dopamine and norepinephrine transporters that increases extracellular levels of dopamine and norepinephrine in vivo. Solriamfetol is a wake-promoting agent.
Przestroga
Hygroscopic
Ta strona może zawierać tekst przetłumaczony maszynowo.
The Journal of pharmacology and experimental therapeutics, 366(2), 367-376 (2018-06-13)
Excessive sleepiness (ES) is associated with several sleep disorders, including narcolepsy and obstructive sleep apnea (OSA). A role for monoaminergic systems in treating these conditions is highlighted by the clinical use of US Food and Drug Administration-approved drugs that act
JZP-110 is a wake-promoting agent with dopaminergic and noradrenergic activity. This double-blind, crossover study, randomized adults with narcolepsy with or without cataplexy (N = 33) to placebo or JZP-110 at 150 mg/day (weeks 1 and 3) increased to 300 mg/day (weeks 2 and 4).
Expert opinion on investigational drugs, 26(8), 953-963 (2017-07-21)
Narcolepsy is a chronic sleep disorder characterized by a pentad of excessive daytime sleepiness (EDS), cataplexy, sleep paralysis, hypnagogic/hypnopompic hallucinations, and disturbed nocturnal sleep. While non-pharmacological treatments are sometimes helpful, more than 90% of narcoleptic patients require a pharmacological treatment.
Questions
Reviews
★★★★★ No rating value
Active Filters
Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.
